Rebetron Combination Therapy

Indication of Rebetron Combination Therapy:

Rebetron Combination Therapy is used for the treatment of chronic hepatitis C in patients who have not before been treated with alfa interferon therapy, or who have relapsed following alfa interferon monotherapy. Patients must be over the age of 18 with compensated liver disease.

Action of Rebetron Combination Therapy:

Rebetron Combination Therapy is made up of therapy with Interferon alfa-2b and Ribavirin.Interferon alfa-2bIntron A Redipen contains Interferon alfa-2b, a member of the family of interferons, substances that are naturally found in the body. Interferons are involved in the immune response to viral infections and other biological mediators. They are involved in preventing spread of viruses through the body, stopping cells multiplying (eg: tumour cells) and enhancing the effects of other immune cells.RibavirinRibavirin is an antiviral agent that has been shown to have activity against a number of different viruses. On its own, it has negligible activity against the hepatitis C virus, but when used in combination with Interferon alfa-2b, its effects have been found to increase tenfold. Therefore, in combination therapy, Ribavirin is useful in the removal of hepatitis C DNA and improvement in liver condition and function.

Dose Advice of Rebetron Combination Therapy:

Rebetol capsules are given at a dose of 1000-1200mg daily in divided doses. 3 x 106 IU Intron A should be administered by injection every other day.Rebetol capsules can be administered without regard to food, but should be given in a consistent manner.Dose of Rebetol depends on body weight: -

• Rebetron combination therapy

• Rebetron combination therapy